Nervous system diseases

This category includes diseases such as epilepsy, Parkinson’s and multiple sclerosis, as well as migraines. To date, the G-BA has assessed 46 different medicinal products in this therapeutic area within the scope of 77 procedures, which in turn were divided into 122 subpopulations. A major additional benefit has been identified for 0.4% of these subpopulations, with a considerable additional benefit seen for 10.4%%. The G-BA has confirmed a minor additional benefit for 9.8% of the subpopulations and a non-quantifiable additional benefit for another 13.6% in relation to the comparative treatment. No additional benefit in relation to the comparative therapy was proved for 65.8% of the subpopulations weighted according to the share of resolutions, corresponding to 88% of the maximum 18.95 million patients treatable with these medicinal products.